EYPT

EyePoint, Inc.

Price Chart

Latest Quote

$4.50

+0.02 (+0.45%)

Current Price

Previous Close	$4.48
Open	$4.44
Day High	$4.58
Day Low	$4.37
Volume	3,505,837

Fetched: 2026-09-01T10:03:59

Stock Information

Shares Outstanding	83.84M
Total Debt	$17.62M
Cash Equivalents	$45.26M
Revenue	$2.79M
Net Income	$-306.64M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$377.29M
EPS (TTM)	$-3.77
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$399.61M
Sales	$2.79M
Income	$-306.64M
Book/sh	$0.40
Cash/sh	$0.54
Employees	214

Financial Ratios

Quick Ratio	4.30
Current Ratio	4.50
Debt/Eq	46.82

Returns & Margins

ROA	-74.85%
ROE	-148.70%
Operating Margin	-450.65%

Ownership

Insider Ownership	3.52%
Institutional Ownership	111.43%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.63
P/S	135.32
P/B	11.36

Analyst Data

Recommendation	buy
Target Price	$27.36

Technical Indicators

SMA20	$9.11
SMA50	$11.72
SMA200	$13.82
RSI	21.83
ATR	1.3643

Shares Float	66.82M
Short Float	22.50%
Short Ratio	10.83
Volatility	1.74
Rel Volume	0.52

Performance History

Week	-7.60%
Month	-63.27%
Quarter	-65.78%
6 Months	-75.46%
YTD	-74.26%
Year	-61.21%
3 Years	-60.90%
5 Years	-55.45%
10 Years	-88.06%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-08-31	$4.50	3,506,000
2026-08-27	$4.63	5,992,900
2026-08-26	$4.99	3,258,000
2026-08-25	$5.01	4,125,000
2026-08-24	$4.87	4,155,600
2026-08-21	$5.32	8,186,400
2026-08-20	$5.40	7,406,300
2026-08-19	$6.30	8,792,900
2026-08-18	$5.47	16,238,000
2026-08-17	$4.87	52,268,300
2026-08-14	$14.75	2,511,100
2026-08-13	$13.48	1,201,900
2026-08-12	$13.53	2,261,400
2026-08-11	$13.05	2,058,500
2026-08-10	$13.07	1,757,000
2026-08-07	$13.89	1,655,700
2026-08-06	$12.83	2,240,700
2026-08-05	$12.25	2,450,100
2026-08-04	$11.67	2,929,700
2026-08-03	$12.42	1,479,400

About EyePoint, Inc.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

📰 Latest News

These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.

Barchart • 2026-08-18T20:22:52Z

EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says

MT Newswires • 2026-08-18T15:09:18Z

EyePoint’s Duravyu falls short to Eylea in Phase III trial

Clinical Trials Arena • 2026-08-18T14:40:10Z

Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls

The Fly • 2026-08-18T13:37:48Z

EyePoint’s Regulatory Overhang May Take Time To Clear After Wet AMD Trial Setback, RBC Says – Retail Calls EYPT Slump A ‘Huge Overreaction’

Stocktwits • 2026-08-18T11:57:25Z

EyePoint (EYPT) LUGANO Data Resets The Story, Is It A Bargain?

Simply Wall St. • 2026-08-18T06:12:06Z

EyePoint (EYPT) Is Down 62.7% After DURAVYU Misses Phase 3 Endpoint In Wet AMD Trial – Has The Bull Case Changed?

Simply Wall St. • 2026-08-18T04:32:56Z

Why Did EYPT, STLA, ENVX Stocks Plunge To 52-Week Lows Today?

Stocktwits • 2026-08-18T03:00:01Z

OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

Stocktwits • 2026-08-17T23:51:33Z

The Surprising Reason EyePoint Just Crashed 67%, Sacrificing A Breakout

Investor's Business Daily • 2026-08-17T20:33:33Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$2,066,000	$3,712,000	$4,632,000	$7,930,000
Cost Of Revenue	$2,066,000	$3,712,000	$4,632,000	$8,326,000
Total Revenue	$31,371,000	$43,273,000	$46,018,000	$41,404,000
Operating Revenue	$31,371,000	$43,273,000	$46,018,000	$41,404,000
Expenses
Interest Expense	$33,000	$14,000	$1,247,000	$3,189,000
Total Expenses	$274,805,000	$189,127,000	$121,085,000	$120,342,000
Net Non Operating Interest Income Expense	$11,751,000	$15,074,000	$5,702,000	$-1,058,000
Interest Expense Non Operating	$33,000	$14,000	$1,247,000	$3,189,000
Operating Expense	$272,739,000	$185,415,000	$116,453,000	$112,016,000
Selling And Marketing Expense	$90,000	$131,000	$11,689,000	$25,507,000
General And Administrative Expense	$51,610,000	$52,358,000	$40,102,000	$34,817,000
Other Income Expense	-	-	$-1,347,000	$-22,258,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Net Interest Income	$11,751,000	$15,074,000	$5,702,000	$-1,058,000
Interest Income	$11,784,000	$15,088,000	$6,949,000	$2,131,000
Normalized Income	$-231,962,000	$-130,870,000	$-69,730,870	$-79,996,000
Net Income From Continuing And Discontinued Operation	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Total Operating Income As Reported	$-243,434,000	$-145,854,000	$-75,067,000	$-99,637,000
Net Income Common Stockholders	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Net Income	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Net Income Including Noncontrolling Interests	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Net Income Continuous Operations	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Pretax Income	$-231,683,000	$-130,780,000	$-70,712,000	$-102,254,000
Special Income Charges	$0	$0	$-1,347,000	$-22,258,000
Interest Income Non Operating	$11,784,000	$15,088,000	$6,949,000	$2,131,000
Operating Income	$-243,434,000	$-145,854,000	$-75,067,000	$-78,938,000
Gross Profit	$29,305,000	$39,561,000	$41,386,000	$33,078,000
Depreciation Amortization Depletion Income Statement	-	-	$0	$2,050,000
Depreciation And Amortization In Income Statement	-	-	$0	$2,050,000
Amortization Of Intangibles Income Statement	-	-	$0	$2,050,000
Per Share
Diluted EPS	$-3.17	$-2.32	$-1.82	$-2.74
Basic EPS	$-3.17	$-2.32	$-1.82	$-2.74
Other
Tax Effect Of Unusual Items	$0	$0	$-282,870	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-229,341,000	$-129,226,000	$-67,654,000	$-74,361,000
Total Unusual Items	$0	$0	$-1,347,000	$-22,258,000
Total Unusual Items Excluding Goodwill	$0	$0	$-1,347,000	$-22,258,000
Reconciled Depreciation	$2,309,000	$1,540,000	$464,000	$2,446,000
EBITDA (Bullshit earnings)	$-229,341,000	$-129,226,000	$-69,001,000	$-96,619,000
EBIT	$-231,650,000	$-130,766,000	$-69,465,000	$-99,065,000
Diluted Average Shares	$73,251,000	$56,298,000	$38,904,000	$37,317,000
Basic Average Shares	$73,251,000	$56,298,000	$38,904,000	$37,317,000
Diluted NI Availto Com Stockholders	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Tax Provision	$279,000	$90,000	$83,000	$0
Research And Development	$221,039,000	$132,926,000	$64,662,000	$49,642,000
Selling General And Administration	$51,700,000	$52,489,000	$51,791,000	$60,324,000
Other Gand A	$51,610,000	$52,358,000	$40,102,000	$34,817,000
Other Special Charges	-	-	$1,347,000	$1,559,000
Impairment Of Capital Assets	-	-	$0	$20,699,000
Amortization	-	-	$0	$2,050,000

Fetched: 2026-08-28

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$306,113,000	$336,501,000	$266,323,000	$96,368,000
Total Assets	$363,996,000	$418,465,000	$355,184,000	$180,356,000
Total Non Current Assets	$35,341,000	$35,159,000	$10,384,000	$7,548,000
Other Non Current Assets	$6,095,000	$5,982,000	$150,000	$150,000
Current Assets	$328,655,000	$383,306,000	$344,800,000	$172,808,000
Other Current Assets	$1,964,000	$1,405,000	$1,009,000	$782,000
Prepaid Assets	$18,141,000	$8,076,000	$8,030,000	$9,076,000
Inventory	$1,813,000	$2,305,000	$3,906,000	$2,886,000
Receivables	$651,000	$607,000	$805,000	$15,503,000
Accounts Receivable	$651,000	$607,000	$805,000	$15,503,000
Cash Cash Equivalents And Short Term Investments	$306,086,000	$370,913,000	$331,050,000	$144,561,000
Cash And Cash Equivalents	$101,821,000	$99,704,000	$281,263,000	$95,633,000
Goodwill And Other Intangible Assets	-	-	-	$0
Other Intangible Assets	-	-	-	-
Debt
Total Debt	$20,772,000	$21,858,000	$4,906,000	$45,769,000
Long Term Debt And Capital Lease Obligation	$20,772,000	$21,858,000	$4,906,000	$35,294,000
Long Term Debt	-	-	-	$29,310,000
Current Debt And Capital Lease Obligation	-	-	-	$10,475,000
Liabilities
Total Liabilities Net Minority Interest	$57,883,000	$81,964,000	$88,861,000	$83,988,000
Total Non Current Liabilities Net Minority Interest	$20,859,000	$32,916,000	$25,598,000	$49,451,000
Other Non Current Liabilities	$87,000	$205,000	-	$600,000
Non Current Deferred Liabilities	$0	$10,853,000	$20,692,000	$13,557,000
Current Liabilities	$37,024,000	$49,048,000	$63,263,000	$34,537,000
Other Current Liabilities	$2,140,000	$1,440,000	$646,000	$579,000
Current Deferred Liabilities	$0	$17,784,000	$38,592,000	$1,205,000
Payables And Accrued Expenses	$20,350,000	$17,994,000	$11,394,000	$12,763,000
Payables	$10,490,000	$11,721,000	$6,504,000	$5,919,000
Accounts Payable	$10,490,000	$11,721,000	$6,504,000	$5,919,000
Equity
Common Stock Equity	$306,113,000	$336,501,000	$266,323,000	$96,368,000
Total Equity Gross Minority Interest	$306,113,000	$336,501,000	$266,323,000	$96,368,000
Stockholders Equity	$306,113,000	$336,501,000	$266,323,000	$96,368,000
Gains Losses Not Affecting Retained Earnings	$961,000	$1,028,000	$864,000	$786,000
Other Equity Adjustments	$961,000	$1,028,000	$864,000	$786,000
Retained Earnings	$-1,104,978,000	$-873,016,000	$-742,146,000	$-671,351,000
Other
Ordinary Shares Number	$82,826,416	$68,266,005	$49,043,074	$34,082,934
Share Issued	$82,826,416	$68,266,005	$49,043,074	$34,082,934
Tangible Book Value	$306,113,000	$336,501,000	$266,323,000	$96,368,000
Invested Capital	$306,113,000	$336,501,000	$266,323,000	$136,153,000
Working Capital	$291,631,000	$334,258,000	$281,537,000	$138,271,000
Capital Lease Obligations	$20,772,000	$21,858,000	$4,906,000	$5,984,000
Total Capitalization	$306,113,000	$336,501,000	$266,323,000	$125,678,000
Additional Paid In Capital	$1,410,047,000	$1,208,421,000	$1,007,556,000	$766,899,000
Capital Stock	$83,000	$68,000	$49,000	$34,000
Common Stock	$83,000	$68,000	$49,000	$34,000
Preferred Stock	$0	$0	$0	$0
Non Current Deferred Revenue	$0	$10,853,000	$20,692,000	$13,557,000
Long Term Capital Lease Obligation	$20,772,000	$21,858,000	$4,906,000	$5,984,000
Current Deferred Revenue	$0	$17,784,000	$38,592,000	$1,205,000
Pensionand Other Post Retirement Benefit Plans Current	$14,534,000	$11,830,000	$12,631,000	$9,515,000
Current Accrued Expenses	$9,860,000	$6,273,000	$4,890,000	$6,844,000
Net PPE	$29,246,000	$29,177,000	$10,234,000	$7,398,000
Accumulated Depreciation	$-6,017,000	$-4,057,000	$-2,571,000	$-2,107,000
Gross PPE	$35,263,000	$33,234,000	$12,805,000	$9,505,000
Leases	$4,180,000	$4,128,000	$1,008,000	$1,008,000
Construction In Progress	$1,460,000	$1,507,000	$3,728,000	$0
Other Properties	$29,623,000	$27,599,000	$8,069,000	$8,497,000
Properties	$0	$0	$0	$0
Work In Process	$584,000	$648,000	$882,000	$1,078,000
Raw Materials	$1,229,000	$1,657,000	$1,303,000	$1,410,000
Other Short Term Investments	$204,265,000	$271,209,000	$49,787,000	$48,928,000
Finished Goods	-	$0	$1,721,000	$398,000
Line Of Credit	-	-	$0	$10,475,000
Current Capital Lease Obligation	-	-	-	$579,000

Fetched: 2026-08-28

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-243,390,000	$-130,278,000	$-1,608,000	$-67,155,000
Operating Activities
Operating Cash Flow	$-240,110,000	$-126,226,000	$1,875,000	$-65,005,000
Cash Flow From Continuing Operating Activities	$-240,110,000	$-126,226,000	$1,875,000	$-65,005,000
Operating Gains Losses	-	-	$1,347,000	$1,559,000
Investing Activities
Capital Expenditure	$-3,280,000	$-4,052,000	$-3,483,000	$-2,150,000
Investing Cash Flow	$68,580,000	$-219,355,000	$-3,315,000	$-17,265,000
Cash Flow From Continuing Investing Activities	$68,580,000	$-219,355,000	$-3,315,000	$-17,265,000
Financing Activities
Issuance Of Capital Stock	$173,445,000	$163,314,000	$226,174,000	$0
Financing Cash Flow	$173,647,000	$164,022,000	$187,070,000	$-690,000
Cash Flow From Continuing Financing Activities	$173,647,000	$164,022,000	$187,070,000	$-690,000
Net Other Financing Charges	$-1,931,000	$-5,184,000	$-1,970,000	$-3,188,000
Net Common Stock Issuance	$173,445,000	$163,314,000	$226,174,000	$0
Common Stock Issuance	$173,445,000	$163,314,000	$226,174,000	$0
Other
Repayment Of Debt	$-105,000	$-105,000	$-45,811,000	$-71,772,000
End Cash Position	$101,971,000	$99,854,000	$281,413,000	$95,783,000
Beginning Cash Position	$99,854,000	$281,413,000	$95,783,000	$178,743,000
Changes In Cash	$2,117,000	$-181,559,000	$185,630,000	$-82,960,000
Proceeds From Stock Option Exercised	$2,238,000	$5,997,000	$3,377,000	$395,000
Net Issuance Payments Of Debt	$-105,000	$-105,000	$-40,511,000	$2,103,000
Net Long Term Debt Issuance	$-105,000	$-105,000	$-40,511,000	$2,103,000
Long Term Debt Payments	$-105,000	$-105,000	$-45,811,000	$-71,772,000
Net Investment Purchase And Sale	$71,705,000	$-215,303,000	$168,000	$-15,115,000
Sale Of Investment	$323,725,000	$183,000,000	$55,284,000	$124,000,000
Purchase Of Investment	$-252,020,000	$-398,303,000	$-55,116,000	$-139,115,000
Net PPE Purchase And Sale	$-3,125,000	$-4,052,000	$-3,483,000	$-2,150,000
Sale Of PPE	$155,000	$0	-	-
Purchase Of PPE	$-3,280,000	$-4,052,000	$-3,483,000	$-2,150,000
Change In Working Capital	$-33,781,000	$-27,773,000	$58,882,000	$-3,023,000
Change In Other Working Capital	$-28,137,000	$-29,028,000	$44,484,000	$-799,000
Change In Other Current Liabilities	$-33,000	$0	-	-
Change In Other Current Assets	$-113,000	$-5,832,000	$0	-
Change In Payables And Accrued Expense	$4,677,000	$5,731,000	$1,519,000	$1,198,000
Change In Inventory	$492,000	$1,600,000	$-1,553,000	$-760,000
Change In Receivables	$-10,667,000	$-244,000	$14,432,000	$-2,662,000
Changes In Account Receivables	$-10,667,000	$-244,000	$14,432,000	$-2,662,000
Other Non Cash Items	$-4,828,000	$-5,953,000	$-856,000	$-558,000
Stock Based Compensation	$27,873,000	$36,740,000	$12,057,000	$14,177,000
Deferred Tax	$279,000	$90,000	$83,000	$0
Deferred Income Tax	$279,000	$90,000	$83,000	$0
Depreciation Amortization Depletion	$2,309,000	$1,540,000	$464,000	$2,446,000
Depreciation And Amortization	$2,309,000	$1,540,000	$464,000	$2,446,000
Depreciation	$2,309,000	$1,540,000	$464,000	$396,000
Net Income From Continuing Operations	$-231,962,000	$-130,870,000	$-70,795,000	$-102,254,000
Issuance Of Debt	-	$0	$5,300,000	$73,875,000
Interest Paid Supplemental Data	-	$0	$1,405,000	$2,600,000
Long Term Debt Issuance	-	$0	$5,300,000	$73,875,000
Provisionand Write Offof Assets	-	$0	$693,000	$1,949,000
Net Short Term Debt Issuance	-	-	$-10,475,000	$10,475,000
Short Term Debt Payments	-	-	$-15,775,000	$-33,400,000
Short Term Debt Issuance	-	-	$5,300,000	$43,875,000
Asset Impairment Charge	-	-	$0	$20,699,000
Amortization Cash Flow	-	-	$0	$2,050,000
Amortization Of Intangibles	-	-	$0	$2,050,000
Income Tax Paid Supplemental Data	-	-	-	$600,000
Effect Of Exchange Rate Changes	-	-	-	-

Fetched: 2026-08-28